Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating SARS-CoV-2 Variants

Our study demonstrates that IVIG lots manufactured in 2023–2024 contain neutralizing antibodies against circulating Omicron variants, including KP.3 and XEC. These variants are resistant to all convalescent plasma and IVIG preparations produced prior to 2023. Therefore, recent IVIG lots may provide...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Vaccines
المؤلفون الرئيسيون: Dongxiao Liu, Lorenza Bellusci, Hana Golding, Surender Khurana
التنسيق: مقال
اللغة:الإنجليزية
منشور في: MDPI AG 2025-07-01
الموضوعات:
COVID-19
SARS-CoV-2
immunoglobulins
convalescent plasma
antibody therapy
treatment
الوصول للمادة أونلاين:https://www.mdpi.com/2076-393X/13/7/760
الوصف
الملخص:Our study demonstrates that IVIG lots manufactured in 2023–2024 contain neutralizing antibodies against circulating Omicron variants, including KP.3 and XEC. These variants are resistant to all convalescent plasma and IVIG preparations produced prior to 2023. Therefore, recent IVIG lots may provide some protection against COVID-19 caused by circulating SARS-CoV-2 variants.
تدمد:2076-393X

مواد مشابهة